Philip Johnson, MS, RPh, FASHP, is the founding Director of Pharmacy at the Moffitt Cancer Center in Tampa, Florida, and is currently the Pharmacy Advocacy Director. His accomplishments at Moffitt include developing and implementing numerous treatment guidelines, a hospital-wide research department, research committee, ethics committee, and ASHP-certified oncology specialty residency. During his career he has opened 3 new hospitals where he developed patient focused, multidisciplinary, clinical pharmacy services.
Mr. Johnson is a founding Director of the Florida Cancer Pain Initiative (FCPI), and the Hematology Oncology Pharmacy Association (HOPA) which he served as President in 2009. He chaired the NCCN workgroup on REMS, and chairs the ISMP taskforce to develop an international oncology medication self assessment tool. He represents ASHP on the AHA Committee on Professions, and is on the ASHP Foundation PLA faculty. Mr. Johnson is the pharmacist representative to the Florida School Health and Education Consortium (SHEC) where he focuses on medication safety and compliance in the Florida public school system, an effort that won an ISMP Cheers Award.
The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.